Rationally designed viruses for use as vaccines or solid tumor therapies
Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.
RSV hospitalizations among adults 65+ no vaccine
Flu cases in 2017-18, current vaccines <37% effective
1 in 8
US women (about 12%) will develop invasive breast cancer during lifetime.
December 02, 2019
Codagenix and USDA-ARS Renew CRADA for Continued Development of Synthetic, Multivalent Foot-and-Mouth Disease Virus (FMDV) Vaccine
Farmingdale, New York, December 2, 2019– Codagenix, Inc., announces today the renewal of a cooperative research and development agreement (CRADA) with the USDA Agricultural Research Service’s (ARS) Foreign Animal Disease Research Unit, located at the Plum Island Animal Disease Center (PIADC) on Plum Island.Full Story
September 27, 2019
Codagenix presenting at ID Week
Come find Codagenix at ID Week, Oct 2-6 in Washington, DC. We are presenting two posters On Oct 5, describing our RSV and tetravalent Dengue vaccines: Poster #2764 : Generation of a Balanced, Tetravalent Dengue Vaccine Based on Contemporary Strains Using a Computational, Synthetic Biology-based Platform Poster #2777 : Synthetic Live-Attenuated Vaccine Against RSV is […]Full Story